The National Cancer Institute is currently recruiting malignant pleural or peritoneal mesothelioma patients
for a phase I clinical trial aimed at patients unable to undergo surgery
and who have not responded to standard first-line treatments for mesothelioma.
LMB-100 is an immunotoxin drug that targets mesothelin, the cancerous protein
expressed in the cells of mesothelioma patients. Although LMB-100 has
shown some effectiveness in previous studies, over time, patients grew
resistant to it. In this study, researchers are hoping to see if injecting
LMB-100 directly into a tumor and combining treatment with the immunotherapy
drug, ipilimumab (brand name Yervoy), will have greater therapeutic effects.
For more study information, including eligibility criteria, visit: